NO2983845T3 - - Google Patents

Info

Publication number
NO2983845T3
NO2983845T3 NO14716337A NO14716337A NO2983845T3 NO 2983845 T3 NO2983845 T3 NO 2983845T3 NO 14716337 A NO14716337 A NO 14716337A NO 14716337 A NO14716337 A NO 14716337A NO 2983845 T3 NO2983845 T3 NO 2983845T3
Authority
NO
Norway
Application number
NO14716337A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2983845T3 publication Critical patent/NO2983845T3/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/545—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
NO14716337A 2012-08-16 2014-04-10 NO2983845T3 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261683956P 2012-08-16 2012-08-16

Publications (1)

Publication Number Publication Date
NO2983845T3 true NO2983845T3 (no) 2017-12-16

Family

ID=50100476

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14716337A NO2983845T3 (no) 2012-08-16 2014-04-10

Country Status (16)

Country Link
US (3) US9523696B2 (no)
EP (2) EP3282258A1 (no)
JP (3) JP6298466B2 (no)
CN (2) CN107478841A (no)
AU (2) AU2013302451B2 (no)
CA (1) CA2882133A1 (no)
DK (1) DK2885641T3 (no)
ES (1) ES2656897T3 (no)
HK (3) HK1250782A1 (no)
IN (1) IN2015DN01259A (no)
MX (1) MX358541B (no)
NO (1) NO2983845T3 (no)
PL (1) PL2885641T3 (no)
RU (2) RU2019107598A (no)
SG (2) SG10201704311VA (no)
WO (1) WO2014028875A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432060B2 (en) 2000-11-09 2008-10-07 The Brigham And Women's Hospital, Inc. Methods for diagnosis of cardiovascular disease
EP3072978B1 (en) 2002-05-09 2018-07-11 The Brigham and Women's Hospital, Inc. 1l1rl-1 as a cardiovascular disease marker
ES2529618T3 (es) 2006-04-24 2015-02-23 Critical Care Diagnostics, Inc. Predicción de la mortalidad y detección de enfermedades graves
PL2482078T3 (pl) 2006-05-01 2016-08-31 Critical Care Diagnostics Inc Diagnozowanie choroby sercowo-naczyniowej
PT2827152T (pt) 2008-04-18 2016-09-13 Critical Care Diagnostics Inc Previsão do risco de eventos cardíacos adversos maiores
HUE027760T2 (en) 2010-04-09 2016-11-28 Critical Care Diagnostics Inc Soluble human ST-2 antibodies and assays
US8728742B2 (en) 2011-03-17 2014-05-20 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
PL2734222T3 (pl) 2011-07-18 2017-03-31 Critical Care Diagnostics, Inc. Sposoby leczenia chorób układu krążenia i prognozowania skuteczności terapii ruchowej
CA2873896A1 (en) 2012-05-18 2013-11-21 Critical Care Diagnostics, Inc. Methods for treating or predicting risk of a ventricular tachyarrhythmia event
JP6298466B2 (ja) 2012-08-16 2018-03-20 クリティカル ケア ダイアグノスティクス インコーポレイテッド 高血圧症を発症するリスクを予測するための方法
MX2015002254A (es) 2012-08-21 2015-05-08 Critical Care Diagnostics Inc Estratificacion de riesgo para marcador multiple.
CA3103560C (en) 2014-09-26 2023-01-17 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
TWI705976B (zh) 2014-11-10 2020-10-01 美商建南德克公司 抗介白素-33抗體及其用途
EP3218515B1 (en) 2014-11-10 2023-04-26 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for il-33-mediated disorders
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
RU2677611C1 (ru) * 2018-04-16 2019-01-17 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Способ прогнозирования неблагоприятных сердечно-сосудистых событий в течение 12 месяцев у больных хронической сердечной недостаточностью с рецидивом стенокардии после реваскуляризации миокарда
US11551817B2 (en) 2020-01-14 2023-01-10 International Business Machines Corporation Assessing unreliability of clinical risk prediction
KR20220152262A (ko) 2020-03-13 2022-11-15 제넨테크, 인크. 항-인터루킨-33 항체 및 이의 용도
RU2767266C1 (ru) * 2021-05-27 2022-03-17 Федеральное государственное бюджетное научное учреждение «Томский национальный исследовательский медицинский центр Российской академии наук» (Томский НИМЦ) Способ прогнозирования однолетнего риска неблагоприятных сердечно-сосудистых событий у мужчин после декомпенсации хронической сердечной недостаточности с сохранной фракцией выброса левого желудочка сердца и синдромом обструктивного апноэ во сне

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001218871A1 (en) 2000-03-21 2001-10-03 Takao Arai Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
US7432060B2 (en) 2000-11-09 2008-10-07 The Brigham And Women's Hospital, Inc. Methods for diagnosis of cardiovascular disease
KR20040068544A (ko) * 2001-11-05 2004-07-31 더 브리검 앤드 우먼즈 하스피털, 인크. 아테롬성 동맥경화증의 예후 표지로서의 가용성 ｃｄ40ｌ(ｃｄ154)
EP3072978B1 (en) 2002-05-09 2018-07-11 The Brigham and Women's Hospital, Inc. 1l1rl-1 as a cardiovascular disease marker
WO2005043123A2 (en) 2003-10-31 2005-05-12 Queststar Medical, Inc. System and apparatus for body fluid analysis using surface-textured optical materials
AU2005311601B2 (en) * 2004-12-03 2011-12-01 Rhode Island Hospital Diagnosis and treatment of Alzheimer's Disease
ES2529618T3 (es) 2006-04-24 2015-02-23 Critical Care Diagnostics, Inc. Predicción de la mortalidad y detección de enfermedades graves
ATE517341T1 (de) 2006-04-27 2011-08-15 Critical Care Diagnostics Inc Interleukin-33 (il-33) zur diagnose und vorhersage von herz-gefäss-erkrankungen
PL2482078T3 (pl) 2006-05-01 2016-08-31 Critical Care Diagnostics Inc Diagnozowanie choroby sercowo-naczyniowej
EP2019965B1 (en) 2006-05-02 2015-04-15 Critical Care Diagnostics, Inc. Differential diagnosis between pulmonary and cardiovascular disease
US8147817B2 (en) * 2006-05-04 2012-04-03 The Brigham And Women's Hospital, Inc. IL-33 in the treatment and diagnosis of diseases and disorders
GB0703514D0 (en) * 2007-02-23 2007-04-04 Univ Ulster Use of riboflavin
US20080300798A1 (en) 2007-04-16 2008-12-04 Mcdevitt John T Cardibioindex/cardibioscore and utility of salivary proteome in cardiovascular diagnostics
ES2401703T3 (es) * 2007-08-03 2013-04-23 B.R.A.H.M.S Gmbh Utilización de la procalcitonina (PCT) en la estratificación de riesgo y el pronóstico de los pacientes con una enfermedad primaria no infecciosa
PT2827152T (pt) 2008-04-18 2016-09-13 Critical Care Diagnostics Inc Previsão do risco de eventos cardíacos adversos maiores
ES2795003T3 (es) 2008-10-07 2020-11-20 Brahms Gmbh Biomarcador para la predicción de los primeros eventos adversos
EP2470910B1 (en) 2009-08-28 2017-01-11 B.R.A.H.M.S GmbH Procalcitonin for the prognosis of adverse events
HUE027760T2 (en) 2010-04-09 2016-11-28 Critical Care Diagnostics Inc Soluble human ST-2 antibodies and assays
GB201013151D0 (en) * 2010-08-04 2010-09-22 Isis Innovation Diagnostic method
US8728742B2 (en) 2011-03-17 2014-05-20 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
PL2734222T3 (pl) * 2011-07-18 2017-03-31 Critical Care Diagnostics, Inc. Sposoby leczenia chorób układu krążenia i prognozowania skuteczności terapii ruchowej
US20130157290A1 (en) * 2011-12-16 2013-06-20 Yves Levy Soluble st2 as a marker for disease
CA2873896A1 (en) * 2012-05-18 2013-11-21 Critical Care Diagnostics, Inc. Methods for treating or predicting risk of a ventricular tachyarrhythmia event
JP6298466B2 (ja) 2012-08-16 2018-03-20 クリティカル ケア ダイアグノスティクス インコーポレイテッド 高血圧症を発症するリスクを予測するための方法
MX2015002254A (es) 2012-08-21 2015-05-08 Critical Care Diagnostics Inc Estratificacion de riesgo para marcador multiple.
CA2935958A1 (en) 2014-01-10 2015-07-16 Critical Care Diagnostics, Inc. Methods and systems for determining risk of heart failure
USD770057S1 (en) 2014-04-14 2016-10-25 Critical Care Diagnostics, Inc. Blood test kit
USD800332S1 (en) * 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
USD800333S1 (en) * 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker

Also Published As

Publication number Publication date
SG11201501200XA (en) 2015-04-29
PL2885641T3 (pl) 2018-04-30
ES2656897T3 (es) 2018-02-28
JP2020196757A (ja) 2020-12-10
JP2015526727A (ja) 2015-09-10
EP2885641A1 (en) 2015-06-24
US20180335437A1 (en) 2018-11-22
JP6757757B2 (ja) 2020-09-23
RU2019107598A (ru) 2019-03-28
CN104737023A (zh) 2015-06-24
HK1250782A1 (zh) 2019-01-11
CN107478841A (zh) 2017-12-15
AU2013302451A1 (en) 2015-03-05
WO2014028875A1 (en) 2014-02-20
CA2882133A1 (en) 2014-02-20
US20170219610A1 (en) 2017-08-03
JP6298466B2 (ja) 2018-03-20
US9523696B2 (en) 2016-12-20
US10041957B2 (en) 2018-08-07
EP2885641B1 (en) 2017-11-01
IN2015DN01259A (no) 2015-07-03
EP2885641A4 (en) 2016-03-23
AU2019202597A1 (en) 2019-05-02
DK2885641T3 (da) 2018-01-29
MX2015002061A (es) 2015-06-05
RU2683026C2 (ru) 2019-03-26
RU2015108959A (ru) 2016-10-10
SG10201704311VA (en) 2017-07-28
MX358541B (es) 2018-08-24
US20140051773A1 (en) 2014-02-20
EP3282258A1 (en) 2018-02-14
CN104737023B (zh) 2017-07-28
JP2018135330A (ja) 2018-08-30
HK1212022A1 (en) 2016-06-03
HK1208075A1 (en) 2016-02-19
AU2013302451B2 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
BR112014017635A2 (no)
BR112014023379A2 (no)
BR112014017614A2 (no)
BR112014017625A2 (no)
BR112014017592A2 (no)
BR112014017659A2 (no)
BR112014017646A2 (no)
BR112014017638A2 (no)
BR112014017607A2 (no)
NO2983845T3 (no)
BR112014017634A2 (no)
BR112014024017A2 (no)
BR112014017609A2 (no)
BR112014017644A2 (no)
BR112014017647A2 (no)
BR112014017618A2 (no)
BR112014017630A2 (no)
BR112014017652A2 (no)
BR112014017621A2 (no)
BR112014017622A2 (no)
BR112014018302A2 (no)
BR112014017627A2 (no)
BR112014017623A2 (no)
BR112014017641A2 (no)
BR112014017631A2 (no)